News-Medical.Net on MSN
Alternative splicing of DOC2A gene shown to drive schizophrenia risk
In an important new study, Chinese researchers have discovered the previously unrecognized role of alternative splicing of ...
In a new study, Chinese researchers have discovered the previously unrecognized role of alternative splicing of the DOC2A ...
A new research paper featured as the cover of Volume 17, Issue 12 of Aging-US was published on December 22, 2025, titled “A ...
News Medical on MSN
Aging Alters RNA Splicing Networks Across the Human Body
Researchers analyzed gene expression and network connectivity across eight human tissues and found shared aging-related ...
Our results demonstrate that differential connectivity analysis reveals significant transcriptional alterations that are not ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( NCT06942572) evaluating SB-007 for the treatment of Stargardt disease.
About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback